Aclaris Therapeutics, Inc. (ACRS): Depreciation & Amortization
$454.0K
Year ended 2025-12-31
$421.0K
Trailing 12 months to 2026-06-30
-17.1%
3-year compound annual growth
-19.3%
5-year compound annual growth
+17.6%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $454.0K | -43.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $807.0K | -6.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $863.0K | +8.3% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $797.0K | -13.7% | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | $923.0K | -30.3% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $1.32M | -79.3% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $6.41M | +241.1% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $1.88M | +367.4% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $402.0K | +235.0% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $120.0K | +33.3% | 2019-03-18, From 2016-01-01 |
| 2015-12-31 | $90.0K | n/a | 2018-03-12, From 2015-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $454.0K | -43.7% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $1.29M | -27.5% |
| Adagene Inc. (ADAG) | 2025-12-31 | $438.9K | -39.3% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $2.54M | -0.7% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $3.35M | -76.2% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $273.0K | -55.5% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $79.0K | -59.1% |
| Immunome Inc. (IMNM) | 2025-12-31 | $2.47M | +57.4% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $219.0K | +6.3% |
Compare ACRS, BOLT, ADAG, XENE side by side · Screen every company in Pharmaceutical Preparations ↗